Somewhat Positive News Coverage Somewhat Unlikely to Impact OpGen (OPGN) Stock Price
Media headlines about OpGen (NASDAQ:OPGN) have been trending somewhat positive on Monday, according to Accern Sentiment Analysis. Accern identifies positive and negative media coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. OpGen earned a media sentiment score of 0.17 on Accern’s scale. Accern also assigned news articles about the medical research company an impact score of 45.7681482227281 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
Here are some of the media stories that may have impacted Accern Sentiment Analysis’s rankings:
- Here’s what’s next for OpGen as it faces delisting threat (finance.yahoo.com)
- Recent Institutional Activity: OpGen, Inc. (OPGN), Gulfport Energy Corporation (GPOR) – Market Movers (financialqz.com)
- An Eye on Data – OpGen, Inc. (NASDAQ: OPGN) – Alpha Beta Stock (alphabetastock.com)
- OpGen (OPGN) Downgraded by Zacks Investment Research (americanbankingnews.com)
- OpGen (OPGN) and NewLink Genetics (NLNK) Head-To-Head Survey (americanbankingnews.com)
OpGen (NASDAQ:OPGN) traded down $0.02 during mid-day trading on Monday, hitting $0.17. The stock had a trading volume of 1,445,100 shares, compared to its average volume of 1,310,367. The company has a market capitalization of $9.74 and a P/E ratio of -0.33. OpGen has a 12 month low of $0.15 and a 12 month high of $1.38. The company has a current ratio of 1.23, a quick ratio of 1.13 and a debt-to-equity ratio of 0.03.
OpGen (NASDAQ:OPGN) last released its earnings results on Tuesday, November 7th. The medical research company reported ($0.07) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.01. OpGen had a negative return on equity of 1,289.51% and a negative net margin of 533.47%. analysts predict that OpGen will post -0.41 EPS for the current year.
OPGN has been the subject of several research analyst reports. Zacks Investment Research downgraded OpGen from a “buy” rating to a “hold” rating in a research report on Wednesday, January 10th. HC Wainwright restated a “buy” rating and set a $1.00 target price on shares of OpGen in a research report on Wednesday, November 8th.
OpGen Company Profile
OpGen, Inc (OpGen) is a precision medicine company using molecular diagnostics and informatics to combat infectious disease. The Company is engaged in developing molecular information solutions to combat infectious disease in global healthcare settings, helping to guide clinicians with information about life threatening infections, managing patient outcomes, and the spread of infections caused by multidrug-resistant microorganisms.
Receive News & Ratings for OpGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OpGen and related companies with Analyst Ratings Network's FREE daily email newsletter.